1H-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent PARP inhibitors
View Patent ↗Compound having formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds having formula (I), methods of treatment comprising compounds having formula (I), and methods of inhibiting the PARP enzyme comprising compounds having formula (I).
1. A compound having formula (I)
or a salt thereof, wherein
R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NR A R B , and (NR A R B )carbonyl;
each R 4 is independently selected from the group consisting of hydrogen, halogen, alkyl, and haloalkyl;
m is 4;
Z is a bond;
A is
each R 5 is independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, hydroxy, hydroxyalkyl, NR C R D , (NR C R D )alkyl, (NR C R D )carbonyl, (NR C R D )carbonylalkyl, and (NR C R D )sulfonyl;
R 6 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, (NR C R D )alkyl, (NR C R D )carbonyl, (NR C R D )carbonylalkyl, and (NR C R D )sulfonyl;
n is 0, 1, 2, or 3; and
R A , R B , R C , and R D are independently selected from the group consisting of hydrogen, alkyl, alkycarbonyl, and cycloalkyl.
2. The compound according to claim 1 having formula (I)
or a salt thereof, wherein
R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen and halogen;
each R 4 is independently selected from the group consisting of hydrogen, halogen, and haloalkyl;
m is 4;
Z is a bond; and
R 6 is selected from the group consisting of alkoxycarbonyl, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, and heterocyclealkyl.
3. The compound according to claim 1 wherein R 4 is hydrogen and R 6 is hydrogen.
4. The compound according to claim 1 wherein R 1 , R 2 , and R 3 are hydrogen.
5. The compound according to claim 1 wherein R 2 is halogen.
6. The compound according to claim 1 wherein each R 4 is hydrogen.
7. A compound selected from the group consisting of
21tert-butyl 2-(4-(4-carbamoyl-1H-benzimidazol-2-yl)phenyl)pyrrolidine-1-carboxylate;
232-(4-(1-isopropylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
242-(4-(1-cyclopentylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
252-(4-(1-cyclohexylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
292-(4-(1-isopropylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
302-(4-(1-cyclopropylmethylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
312-(4-(1-cyclopentylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
322-(4-(1-cyclohexylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
332-(4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
342-(4-(1-propylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
352-(4-(1-cyclopropylmethylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
362-(4-(1-propylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
383-(4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
392-(4-(1-methylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
402-(4-(1-methylpyrrolidin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide;
446-chloro-2-(4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
456-Fluoro-2-(4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
466-chloro-2-(4-(1-isopropyl-pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
476-chloro-2-(4-(1-cyclopentyl-pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
486-Chloro-2-(4-(1-methylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
496-fluoro-2-(4-(1-methylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
50F2-(2-fluoro-4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
502-(4-(1-ethylpyrrolidin-2-yl)-2-fluorophenyl)-1H-benzimidazole-4-carboxamide;
512-(2-fluoro-4-(1-isopropylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
522-(4-(1-Cyclobutylpyrrolidin-2-yl)-2-fluorophenyl)-1H-benzimidazole-4-carboxamide;
532-(2-Fluoro-4-(1-propylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
542-(4-(1-cyclopropylmethylpyrrolidin-2-yl)-2-fluorophenyl)-1H-benzimidazole-4-carboxamide;
556-fluoro-2-(2-fluoro-4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide;
566-fluoro-2-(2-fluoro-4-(1-isopropylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
572-(4-(1-Ethylpyrrolidin-2-yl)-2-fluorophenyl)-6-fluoro-1H-benzimidazole-4-carboxamide;
56-Fluoro-2-(2-fluoro-4-(1-methylpyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide;
92(+)(R)-2-(2-fluoro-4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide; and
93(−)(S)-2-(2-fluoro-4-pyrrolidin-2-ylphenyl)-1H-benzimidazole-4-carboxamide.
8. A composition comprising a compound having formula (I) of claim or salt thereof, and therapeutically acceptable carrier.